Control Bionics Ltd Cash Flow Conversion Efficiency
Control Bionics Ltd cash flow conversion efficiency. Based on the latest financial reports, Control Bionics Ltd (CBL) has a cash flow conversion efficiency ratio of -0.559x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.53 Million ≈ $-2.49 Million USD) by net assets (AU$6.31 Million ≈ $4.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Control Bionics Ltd (2017–2025)
Cash flow conversion efficiency of Control Bionics Ltd from 2017 to 2025. This chart illustrates how Control Bionics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Control Bionics Ltd (CBL) stock price for real-time trading data and today's change.
Control Bionics Ltd Cash Flow Conversion Ratio Explained
Control Bionics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Control Bionics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Control Bionics Ltd ranked by their cash flow conversion efficiency. Also see how much is Control Bionics Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SANUWAVE Health, Inc. Common Stock
NASDAQ:SNWV
|
0.216x |
|
Bannari Amman Spinning Mills Limited
NSE:BASML
|
0.052x |
|
Ordinary Fully Paid Deferred Settlement
AU:88EDA
|
N/A |
|
Prakit Holdings Public Company Limited
BK:PRAKIT
|
-0.040x |
|
Catenon S.A
MC:COM
|
0.241x |
|
Murudeshwar Ceramics Limited
NSE:MURUDCERA
|
0.023x |
|
PERFORMANCE SHIPP.
F:DS2
|
0.030x |
|
Lipidor Ab
ST:LIPI
|
-0.274x |
Annual Cash Flow Conversion Efficiency for Control Bionics Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Control Bionics Ltd from 2017 to 2025. Review CBL free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | AU$6.31 Million ≈ $4.47 Million |
AU$-5.75 Million ≈ $-4.07 Million |
-0.911x | -17.50% |
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
AU$-4.27 Million ≈ $-3.02 Million |
-0.775x | +1.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
AU$-4.91 Million ≈ $-3.48 Million |
-0.784x | -23.18% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
AU$-4.53 Million ≈ $-3.20 Million |
-0.636x | -10.15% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
AU$-6.89 Million ≈ $-4.87 Million |
-0.578x | -148.41% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
AU$-3.99 Million ≈ $-2.82 Million |
-0.233x | -441.59% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
AU$-864.05K ≈ $-611.37K |
-0.043x | +88.85% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
AU$-1.95 Million ≈ $-1.38 Million |
-0.385x | -141.49% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
AU$-970.84K ≈ $-686.93K |
-0.159x | -- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more